Eloxx Pharmaceuticals, Inc. (ELOX)

Eloxx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Selling, General & Admin	10.69	20.45	14.85	24.21	26.48
Research & Development	23.73	45.57	14.59	26.35	20.49
Other Operating Expenses	0.08	0	0	0	0
Operating Expenses	34.42	66.02	29.44	50.56	46.97
Operating Income	-34.42	-66.02	-33.46	-50.56	-47.57
Interest Income	0.27	0.01	0.34	1.07	0.6
Interest Expense	1.95	1.26	1.41	1.62	0.01
Other Expense / Income	-2.06	-1.8	-1.36	-1.84	0.09
Pretax Income	-36.07	-66.73	-34.58	-50.87	-47.06
Income Tax	2.03	1.26	1.41	1.62	0.12
Net Income	-36.07	-66.73	-34.58	-50.87	-47.19
Shares Outstanding (Basic)	2	2	1	1	1
Shares Outstanding (Diluted)	2	2	1	1	1
Shares Change	23.85%	74.36%	5.42%	17.35%	551.81%
EPS (Basic)	-16.65	-38.15	-34.47	-53.46	-58.19
EPS (Diluted)	-16.65	-38.15	-34.47	-53.46	-58.19
Free Cash Flow	-31.91	-35.09	-28.17	-39.43	-31.6
Free Cash Flow Per Share	-14.73	-20.06	-28.08	-41.44	-38.97
EBITDA	-33.37	-65.05	-28.53	-48.92	-46.15
Depreciation & Amortization	0.7	0.96	0.57	0.56	0.22
EBIT	-34.07	-66.01	-29.1	-49.48	-46.37

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.